Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Simply Wall St.

May 14

The quarterly results for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released last week, making it a good time to revisit its performance. The results look positive overall; while revenues...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2635306587"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635306587\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635306587?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-14 02:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635306587","market":"hk","top_or_hot":-1,"title":"Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think","media":"Simply Wall St.","content":"<div>\n<p>The quarterly results for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released last week, making it a good time to revisit its performance.        The results look positive overall; while revenues...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-enta/enanta-pharmaceuticals/news/enanta-pharmaceuticals-inc-nasdaqenta-just-released-its-seco-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-14 02:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-enta/enanta-pharmaceuticals/news/enanta-pharmaceuticals-inc-nasdaqenta-just-released-its-seco-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The quarterly results for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released last week, making it a good time to revisit its performance.        The results look positive overall; while revenues...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-enta/enanta-pharmaceuticals/news/enanta-pharmaceuticals-inc-nasdaqenta-just-released-its-seco-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-enta/enanta-pharmaceuticals/news/enanta-pharmaceuticals-inc-nasdaqenta-just-released-its-seco-1","article_id":"2635306587","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-enta/enanta-pharmaceuticals/news/enanta-pharmaceuticals-inc-nasdaqenta-just-released-its-seco-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635306587","pubTimestamp":1778698513,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The quarterly results for Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) were released last week, making it a good time...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite","ENTA":"Enanta Pharmaceuticals Inc."},"translate_title":"Enanta Pharmaceuticals，Inc.（纳斯达克：ENTA）刚刚发布了第二季度收益：以下是分析师的看法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1.5,"ENTA":1.5},"content_text":"The quarterly results for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released last week, making it a good time to revisit its performance.        The results look positive overall; while revenues of US$17m were in line with analyst predictions, statutory losses were 7.7% smaller than expected, with Enanta Pharmaceuticals losing US$0.45 per share.      Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company.  We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGS:ENTA Earnings and Revenue Growth May 13th 2026 After the latest results, the consensus from Enanta Pharmaceuticals' five analysts is for revenues of US$66.9m in 2026, which would reflect a measurable 3.3% decline in revenue compared to the last year of performance.      Per-share losses are predicted to creep up to US$2.21.       Yet prior to the latest earnings, the analysts had been forecasting revenues of US$67.7m and losses of US$2.04 per share in 2026.         So it's pretty clear consensus is mixed on Enanta Pharmaceuticals after the new consensus numbers; while the analysts held their revenue numbers steady, they also administered a modest increase to per-share loss expectations.      See our latest analysis for Enanta Pharmaceuticals   As a result, there was no major change to the consensus price target of US$20.14, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses.         The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is.  Currently, the most bullish analyst values Enanta Pharmaceuticals at US$28.00 per share, while the most bearish prices it at US$19.00.   There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.      These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Enanta Pharmaceuticals' past performance and to peers in the same industry. We would also point out that the forecast 6.5% annualised revenue decline to the end of 2026 is better than the historical trend, which saw revenues shrink 9.1% annually over the past five years   By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 22% per year.  So while a broad number of companies are forecast to grow, unfortunately Enanta Pharmaceuticals is expected to see its revenue affected worse than other companies in the industry.     AdvertisementThe Bottom Line  The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Enanta Pharmaceuticals.        On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry.       There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.   Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider.   We have estimates - from multiple Enanta Pharmaceuticals analysts - going out to 2028, and you can see them free on our platform here.  You should always think about risks though. Case in point, we've spotted   2 warning signs for Enanta Pharmaceuticals  you should be aware of, and 1 of them shouldn't be ignored.   Valuation is complex, but we're here to simplify it.Discover if Enanta Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}